Cargando…
Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
SIMPLE SUMMARY: Second-line systematic therapy options for soft-tissue sarcoma (STS) have remained unchanged for decades due to the rarity and various histological types associated with STS. Challenges with molecular-targeted treatments for STS led to the approval of pazopanib and its wide use for S...
Autores principales: | Sato, Yasuyoshi, Nakano, Kenji, Wang, Xiaofei, Fukuda, Naoki, Urasaki, Tetsuya, Ohmoto, Akihiro, Hayashi, Naomi, Yunokawa, Mayu, Ono, Makiko, Tomomatsu, Junichi, Saito, Masanori, Minami, Yusuke, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Takahashi, Shunji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699255/ https://www.ncbi.nlm.nih.gov/pubmed/34944888 http://dx.doi.org/10.3390/cancers13246266 |
Ejemplares similares
-
Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021) -
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
por: Ohmoto, Akihiro, et al.
Publicado: (2023) -
Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019) -
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial
por: Sato, Yasuyoshi, et al.
Publicado: (2020) -
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients
por: Fukuda, Naoki, et al.
Publicado: (2020)